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E-mail address: abdu.alayash@fda.hhs.gov (A.I. AlaWe examined carbon monoxide (CO) delivery by carbon monoxide-releasing molecule 2 (CORM-2)
or hemoglobin (Hb) on cellular oxygen sensing andmitochondrial respiration in bovine aortic endo-
thelial cells (BAECs). CORM-2 reduced hypoxia-inducible factor-1a (HIF-1a) and endothelin-1 (ET-1)
expression in normoxic and hypoxic cells, but while Hb alone signiﬁcantly reduced HIF-1a stabiliza-
tion in hypoxic cells, CO delivered by Hb (Hb-CO) had no effect on HIF-1a stabilization. CO dose-
dependently increased basal oxygen consumption and reduced overall mitochondrial respiratory
capacity. Hb-CO increased basal oxygen consumption but did not alter respiratory capacity.
Together, CO reduced ET-1, and, at low doses, had no effect on endothelial mitochondria oxygen
consumption. CO ligation to Hb may be developed further as non-vasoactive oxygen therapeutic
without compromising mitochondrial function.
Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies.1. Introduction have been at the forefront of potential therapeutic applicationsCO is an endogenously produced natural byproduct of heme
catabolism by the enzyme heme oxygenase. The primary known
molecular target of CO is the heme iron center of hemoproteins,
such as Hb and mitochondrial cytochromes, in which high and pro-
longed exposure to CO results in classical CO-poisoning [1]. Emerg-
ing research has shown that low levels of CO can act as an
important signaling molecule with broad physiological effects on
the vasculature. CO was found to play a key role in various inﬂam-
matory and cardiovascular events, and many of these signaling
pathways have become attractive targets for drug devolvement.
Besides its beneﬁcial antioxidant effects, CO was shown to have
additional vasodilatory effects similar to nitric oxide (NO), the pen-
ultimate vasoactive molecule produced by the vascular system.
Activation of soluble guanylyl cyclyase (sGC), increases in cGMP
content, and direct activation of calcium-activated potassium
channels have been shown to be involved in CO-induced vasodila-
tion [2,3]. The development of CO-releasing molecules (CORMs),
which are designed to deliver CO locally in a controlled manner,Federation of European Biochemi
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yash).[4,5]. The CO-releasing properties of ﬁrst generation CORMs were
reported to be at t1/2P 1 min in vivo, ex vivo, and in vitro biolog-
ical models [6]. The kinetics of CO release from Hb is more com-
plex, particularly when Hb is free in solution. Additionally, Hb
exists in an equilibrium between two different conformational
states: the oxygenated R (relaxed) and deoxygenated T (tense)
states. It has been estimated that the rate-limiting step for CO
delivery is the R-state off-rate, giving an overall t1/2 for the reaction
of approximately 30–40 s [7].
The presence of cell-free Hb in circulation as result of hemolytic
anemias or when Hb is used as oxygen-carrying blood substitutes
can present numerous serious complications including an immedi-
ate raise in systemic and pulmonary blood pressure due to removal
of NO and subsequent tissue-damaging oxidative toxicity [8]. The
use of NO donating compounds or nitrite have been advocated as
possible countermeasures that can be infused with Hb to control
hemodynamic imbalances in anemic patients or in patients ex-
posed to hemoglobin-based oxygen carriers (HBOCs) [9]. NO-in-
duced oxidation of free Hb and possible heme loss motivated the
search for safer HBOCs. HBOCs carrying CO is currently being
developed as a strategy to reduce toxicity, maintain oxygen deliv-
ery, and promote vasodilation. CO is known for its cell signaling as
well as for its antioxidative and vasodilatory actions [1,4]. Hb-CO
derivatives have been manufactured with the notion that transfu-
sion of these molecules will perform dual functions as CO and oxy-
gen delivery agents, once CO is released from Hb [7]. Hb
conjugated to polyethylene glycol and ligated to CO was recently
shown to reduce myocardial infarcts in rats [7].cal Societies. Open access under CC BY-NC-ND license.
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trates the cellular response to low oxygen tension, as reviewed
elsewhere [10]. HIF-1a, in turn, links hypoxic events to the regula-
tion of vascular tone by driving expression of ET-1, a potent vaso-
constrictor secreted from endothelium [11]. In this report, we
examine endothelial oxygen sensing by HIF-1a and, for the ﬁrst
time, real-time mitochondrial oxygen consumption following CO
delivery from CORM-2 and Hb-CO. CORM-2 reduced HIF-1a and
ET-1 expression while maintaining normal mitochondria oxygen
consumption. At higher doses, CORM-2 disrupted mitochondrial
function. When delivered by Hb, CO did not alter mitochondrial
function, but failed to reduce HIF-1a expression in hypoxic endo-
thelial cells. These ﬁndings may directly relate to recent attempts
by many to overcome the well-known vasculopathy associated
with the infusion of Hb as oxygen therapeutics [12].2. Materials and methods
2.1. Cell culture
Bovine aortic endothelial cells (BAECs) were cultured under
normoxic and hypoxic conditions as described [13]. CORM-2 and
RuCl3 (control for CORM-2) were purchased from Sigma (St. Louis,
MO) and dissolved in DMSO stocks. For hypoxia treatment, cells
were gassed with 1% O2 using a Modular Incubator Chamber from
Billups–Rothenburg (Del Mar, CA).
To assess effects of O2 and CO-ligated forms of Hb on endothe-
lial cells, BAECs were grown to conﬂuence on 12-well Transwell ﬁl-
ter plates (Corning Life Sciences, Pittston, PA). Highly puriﬁed
stroma free bovine Hb, used as a control in this study, was a kind
gift from OPK Corporation, Cambridge, MA. Pegylated bovine Hb li-
gated to CO was a kind gift from Prolong Pharmaceuticals, South
Plainﬁeld, NJ. The isolation and manufacturing and the pegylation
process of this Hb was described previously [14]. This PEG-Hb-CO
is referred to throughout the manuscript for simplicity as Hb-CO.
BAECs were serum-starved 2 h, and serum-free media was chan-
ged again immediately before beginning the experiment with
500 lL in the top chamber and 700 lL in the bottom chamber.
Hb ± CO (2 mM stock, 800 lL) was added to the bottom chamber
(ﬁnal Hb ± CO 1.07 mM in bottom chamber). Cells were incubated
in 1% O2 and at 37 C for 2 h before harvesting for immunoblot
analysis.
2.2. Immunoblot analysis
Cells were lysed in Novex Tricine SDS sample buffer (Invitrogen,
Carlsbad, CA) supplemented with 2% b-ME (Sigma) for separation
by SDS–PAGE. The HIF-1a antibody was from R&D Systems (Min-
neapolis, MN), and the b-actin antibody was from Sigma. The sec-
ondary HRP-linked antibodies were from Santa Cruz Biotechnology
(Santa Cruz, CA). Immunoblots were visualized with Lumiglo (Cell
Signaling Technology, Danvers, MA) and exposure to Amersham
Hyperﬁlm MP (Buckinghamshire, UK). Images were scanned and
analyzed with NIH Image J software (Bethesda, MD).
2.3. Endothelin-1 (ET-1) ELISA
The ET-1 ELISA kit obtained from Enzo Life Sciences (Ann Arbor,
MI) was used according to the manufacturer’s protocol to measure
ET-1 secreted into cell culture media.
2.4. XF24 mitochondria oxygen consumption analysis
The OCR of BAECs was measured in real-time using XF24 tech-
nology from Seahorse Biosciences (Billerica, MA) essentially as de-scribed for BAECs [15]. BAECs were grown to conﬂuence on the 24-
well XF cell culture plate before all experiments. One hour prior to
experimentation, BAEC cell culture media (from above) was chan-
ged to serum-free and bicarbonate-free DMEM supplemented with
1000 mg/L glucose and L-glutamine (Sigma, D5523), and 1 mM
pyruvate fromMediatech, Inc. (Herndon, VA), and pH was adjusted
to 7.4 with NaOH. The oligomycin, FCCP, and rotenone used in
XF24 experiments were all from Sigma, and dose–response exper-
iments determined that the optimal amounts of compounds for our
BAECs were 0.5 lg/mL (oligomycin), 3 lM (FCCP), and 1 lM (rote-
none). A typical evaluation of BAEC OCR in response to optimized
inhibitors is described in Fig. 2. Data from multiple experiments
are expressed in terms of percent change in OCR, and the OCR for
area under the curve (AUC) measurements is expressed as pmol/
min.
2.5. Statistics
Data are presented as mean ± SEM. Statistical analyses
were performed using ANOVA or Student’s t-test as described in
the ﬁgure legends. Differences were considered signiﬁcant at
p < 0.05.3. Results
3.1. CORM-2 blocks HIF-1a stabilization and ET-1 expression in
endothelial cells
We ﬁrst examined the effects of CORM-2 on HIF-1a and ET-1
expression in endothelial cells. BAECs were treated with increasing
doses of the control RuCl3 or CORM-2. Fig. 1A depicts a representa-
tive immunoblot. HIF-1a expression remained stable until cells
were treated with 50 or 100 lM CORM-2. Correspondingly, ET-1
secretion by BAECs was also reduced slightly after treatment with
50 lM CORM-2, and was signiﬁcantly lower after treatment with
100 lM CORM-2 (Fig. 1B). Therefore, CO delivered by CORM-2 re-
duced basal HIF-1a and its downstream target ET-1 in endothelial
cells under normoxic conditions.
Next, we examined HIF-1a expression in response to CORM-2
under hypoxic conditions. Conﬂuent BAECs were treated for one
hour with or without CORM-2 prior to hypoxia (1% O2) or contin-
ued normoxic conditions. A representative immunoblot and image
analysis is shown in Fig. 1C. Hypoxia, as expected, increased HIF-
1a protein content of BAECs. CORM-2 (100 lM), as Fig. 1A shows,
reduced HIF-1a expression in normoxic cells. BAECs that were
treated ﬁrst with CORM-2 had reduced HIF-1a protein expression
following the hypoxic challenge. Therefore, CORM-2 reduces basal
HIF-1a expression and attenuated upregulation of HIF-1a expres-
sion in hypoxic endothelial cells.
3.2. Measurements of mitochondrial function in BAECs using XF24-
extracellular ﬂux analyzer
A Seahorse Bioscience XF24 extracellular analyzer was used
to measure mitochondrial function in intact BAECs. The principle
and operation of this technology has been recently reviewed
[16]. Conﬂuent BAECs were used in our model system, and this
yielded a comparable OCR proﬁle to that of previously published
results [14] in BAECs (see Fig. 2). By using the indicated oxida-
tive phosphorylation inhibitors, the OCR that corresponds to
ATP production and maximal oxygen consumption by the mito-
chondria can be calculated. Therefore, we can exquisitely mea-
sure CO impacting mitochondrial function at cytochrome c
oxidase [17] in real-time following CO delivery by CORM-2 or
Hb.
Fig. 1. CORM-2 reduces HIF-1a protein stabilization. (A) BAECs were treated with
increasing doses of the CO-donor CORM-2 (0 lM through 100 lM) for 6 h and
analyzed for HIF-1a protein by immunoblot analysis. HIF-1b and actin serve as
constitutive loading controls. Immunoblots are representative of three independent
experiments. (B) BAECs were treated with the indicated doses as in A for 6 h and
analyzed for ET-1 expression by ELISA. ⁄p < 0.01 by Student t-test. (C) BAECs were
treated without or with CORM-2 for 1 h before incubation under hypoxia (hx, 1%
O2) or air for an additional 5 h. A representative immunoblot is shown, and
densotometric image analysis demonstrates a reduction of HIF-1a protein following
CORM-2 treatment under normoxia and hypoxia (n = 3, ⁄p < 0.05 by ANOVA and
Tukey–Kramer post-test).
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We examined mitochondrial OCR using XF24 technology in
BAECs in response to a wide range of CORM-2 concentrations. As
shown in Fig. 3A, BAECs were treated with 0–250 lM (higher
500 lM doses are not shown for clarity), and approximately
50 min later, basal OCR begins to steadily increase in BAECs treated
with 100 or 250 lM CORM-2. The effects of oligomycin and FCCP
were also blunted in cells treated with 100 or 250 lM CORM-2.
Next, the area under the curve (AUC) that corresponds to basal
OCR (t = 23–150 min in Fig. 3A), OCR due to ATP production
(t = 150–170 min in Fig. 3A), and OCR that represents total respira-
tory capacity (t = 170–186 min in Fig. 3A) were calculated. As little
as 50 lM CORM-2 had no effect on any mitochondrial oxygen-con-
sumption parameter, but 100 lM or greater CORM-2 concentra-
tions progressively disrupted mitochondrial function as reﬂected
in increasing basal OCR or decreasing OCRs corresponding to ATP
production and respiratory capacity. However, 500 lM CORM-2
appeared highly toxic resulting in negative calculations of respira-
tory capacity. The 50 lM CORM-2 dose that had little impact on
cellular mitochondrial oxygen consumption is still greater than
the 20 lmol/kg CORM-2 dose that that was reported to signiﬁ-
cantly reduce rat mean arterial pressure [18].
3.4. CO bound to Hb does not disrupt mitochondrial OCR nor inhibit
HIF-1a stabilization
We examined mitochondrial OCR and HIF-1a expression in
endothelial cells to evaluate Hb-CO potential toxicity and oxygen
delivery, respectively. First, BAECs were examined for OCR while
co-incubated with Hb or Hb-CO. The XF-24 Analyzer limits the
amount of Hb that can be injected to co-culture with cells, there-
fore we examined 50 lM heme, a maximum concentration that
can be used without compromising the operation of the XF-24
Analyzer. As shown in Fig. 4A, the OCR of cells treated with control
vehicle, Hb, or Hb-CO is nearly identical. In calculating AUC, only
the basal rate following treatment with either Hb or Hb-CO in-
duced a slight increase in OCR for t = 23–150 min (Fig. 4B). Treat-
ment with the various mitochondrial inhibitors did not alter OCR
compared with control. Therefore, Hb alone may induce alterations
in OCR, which requires further investigation, but the addition of CO
in the form of Hb-CO had no measurable effect on mitochondrial
OCR.
Next, BAECs were exposed to hypoxia (1% O2) and co-cultured
with Hb or Hb-CO, as described in Section 2, to ascertain oxygen
delivery to cells (Fig. 4C). HIF-1a expression was assessed as a bio-CP Rotenone
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Fig. 3. CORM-2 dose-dependently disrupts mitochondrial function in BAECs. (A) Representative OCR data of CORM-2 treatment of BAECs with XF24 technology (D/
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Fig. 3A. CO inhibits complex IV. Increasing CORM-2 progressively increased basal OCR resulting in decreased OCR for ATP production and reduced overall respiratory capacity
and reserve capacity (⁄p < 0.05 and p < 0.01 by ANOVA and Dunnett’s post-test compared to DMSO control of basal OCR, OCR due to ATP production, or OCR due to respiratory
capacity, respectively). There was no statistical effect with 50 lM CORM-2.
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cultured with Hb had reduced HIF-1a expression in a hypoxic envi-
ronment compared with BAECs co-cultured without Hb (Fig. 4C,
compare lanes 1 and 2). However, BAECs that were co-cultured
with Hb-CO had elevated HIF-1a expression, suggesting that oxy-
gen delivery to the cells was reduced, possibly due to CO ligation
to the heme iron (compare lanes 1 and 3).
4. Discussion
The possibility of CO binding to mitochondrial respiratory chain
components and consequent impairments in oxygen consumption
led us to investigate CO delivery by CORM-2 and by a CO ligated to
chemically modiﬁed hemoglobin (Hb-CO). First, we determined
the levels of HIF-1a expressions in vascular endothelial cells to as-
sess the impact of increasing levels of CORM-2 on cellular oxygen
sensing mechanisms within these cells grown under normoxia and
hypoxia. Our data clearly show that increasing doses of CO sup-
press the expression of HIF-1a and its downstream target ET-1
(Fig. 1A and B), in support of observations made by others
[19,20]. Under hypoxic (1% O2) stimulation of HIF-1a stabilization,
HIF-1a expression was reduced with CORM-2 pretreatment
(Fig. 1C), suggesting CORM-2 may enhance HIF-1a degradation or
interfere with HIF-1a stabilization. Chin et al. [21] demonstrate
that treatment of macrophages with CORM resulted in a rapid
up-regulation of HIF-1a that peaked at 30 min and returning to
control levels within an hour; however, catalase (ROS scavenger)
abrogated the stabilization of HIF-1a. Astrocytes also upregulated
HIF-1a in response to CORM-2 [22], highlighting the varied cell-
and tissue-speciﬁc responses to CO treatment. As a consequence
of HIF-1a inhibition in our experiments, ET-1 expression wasclearly inhibited as the conceration of CORM-2 increased
(Fig. 1B). Since ET-1 secreted by the endothelium is known for its
potent vasoconstrictor activity, the suppression of its expression
may explain, in part, the vasodilatory activity reported on the
use of CO.
We used the extracellular ﬂux analyzer to measure mitochon-
drial function in BAECs in order to determine the effects of
CORM-2 on the OCR, which correlates with electron transport
chain function. We found that CORM-2 dose-dependently im-
pacted mitochondrial function in these cells by increasing the basal
resting-state OCR. This lead to decreases of the OCR that corre-
spond to ATP production and overall respiratory capacity of the
mitochondria. Based on studies with CORM-3, this is likely due
to a combination of cytochrome c oxidase inhibition and uncou-
pling of the electron transport chain leading to a loss of the proton
gradient [23]. However, both Hb and Hb-CO showed little or no ef-
fects on overall mitochondrial function and biogenetics, except a
small, but signiﬁcant, rise in basal OCR (Fig. 4A and B). Probing
mitochondrial function with inhibitors revealed no other altera-
tions in OCR. Ferrous Hb however, suppressed the expression
HIF-1a whereas Hb-CO shows no effect on oxygen sensing ele-
ments due to blockage of Hb iron by CO. This suggests that time-
in-circulation is required for CO off-loading and oxygen uptake
and delivery by an HBOC utilizing this technology.
Gas messengers, such as CO and NO, and redox regulation by
HIFs represent a different perspective in modulating potential
therapeutic targets for normalizing cardiac, vascular, and respira-
tory disease states [24]. While it is unclear how CO reduces HIF-
1a protein levels following CORM-2 and to lesser extent with
Hb-CO treatment, there may be at least two possible scenarios:
(1) CO may directly attenuate HIF-1a gene expression; or (2) CO
Fig. 4. CO delivered by Hb increases basal OCR but does not deliver oxygen. (A) Representative OCR data of CORM-2 treatment of BAECs with XF24 technology (C/Hb = media,
Hb, or Hb-CO, O = oligomycin, F = FCCP, R = rotenone). (B) Hb and Hb-CO induced an increase in basal OCR between time of Hb or control treatment at t = 23 min and
oligomycin treatment at t = 151 min in A (⁄p < 0.05 by ANOVA and Tukey–Kramer post-test compared with vehicle). (C) BAECs were co-cultured in hypoxia either alone () or
with Hb or Hb-CO to mimic an HBOC therapeutic to deliver oxygen. Only Hb, without CO (lane 2), delivered oxygen to reduce HIF-1a expression in hypoxic BAECs.
Immunoblot is representative of three independent experiments.
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scenario, a disruption of the mitochondrial OCR by these com-
pounds could transiently increase intracellular oxygen substrate
availability for PHD2, leading to enhanced HIF-1a degradation
[24]. Chemically modiﬁed and stabilized Hb saturated with CO,
in contrast to rapidly delivered CO by CORMs [25], represents an-
other amenable option. This has recently been demonstrated in
several transgenic mouse models of sickle cell disease in which
vascular damage and even mortality was prevented under hypoxia
[26]. Moreover, CO ligated to the ferric form of Hb was recently
found to not only autoreduce its iron back to Fe2+, but it can also
promote iron reduction in the respiratory chain hemoproteins un-
der oxidative stress conditions and in the presence electron donat-
ing oxidants [27]. Together, the use of CO with chemically modiﬁed
Hb may enhance the safe use of oxygen therapeutics and the devel-
opment of new applications to treat sickle cell disease.
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